Efectividad de la autohistovacuna a partir de papilomas cutáneos extraídos en perros atendidos en la clínica veterinaria UTMACH.

Abstract

Canine cutaneous papillomatosis is a viral disease caused by Canine Papillomavirus (CPV), commonly affecting young or immunocompromised dogs through the appearance of warty lesions on the skin and mucous membranes. Although lesions are often self-limiting, in some cases they persist or worsen, requiring accessible and effective therapeutic alternatives. In this context, autohistovaccines prepared from the patient's own papillomatous tissue emerge as an innovative treatment that stimulates the immune system to control the infection. This study aimed to evaluate the clinical effectiveness of autohistovaccine in two dogs treated at the Veterinary Specialty Teaching Clinic of the Technical University of Machala. An experimental design with a qualitative-quantitative approach was applied. Each patient received three subcutaneous doses at weekly intervals. Clinical evaluation included initial lesion characterization, recovery time, adverse reactions, and recurrence during follow-up. Results showed complete lesion remission in both cases, with no adverse effects or recurrence. One patient exhibited marked improvement after the first dose, while the other responded gradually by the third application. These findings suggest that autohistovaccines are a safe, cost-effective, and viable therapeutic tool, especially in regions with limited access to conventional veterinary treatments. Further research with a larger sample size and extended follow-up is recommended to confirm long-term efficacy and broaden clinical applications.